Back

Rznomics gets positive EMA opinion for RZ-001 orphan designation in glioma

Verifying
  • Rznomics received a positive EMA COMP opinion supporting orphan designation for RZ-001 in glioma.
  • RZ-001 has treated 10 trial patients and three under the U.S. FDA Expanded Access Program.
  • Formal European Commission designation would provide incentives including up to 10 years' market exclusivity.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Rznomics gets positive EMA opinion for RZ-001 orphan designation in glioma - CoinPost Terminal